Keytruda pembrolizumab: Phase II data

Top-line data from 30 evaluable patients with relapsed or refractory classical Hodgkin’s lymphoma in the open-label Phase II KEYNOTE-087 trial showed that 200 mg IV

Read the full 257 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE